Multiscale Computational Studies of PEG Chain Length Effects on HER2 mAb Fc Structure and Binding Energetics

Heather A Noriega1,2, Emmanuel O Akala2, Xiang Simon Wang1,2

  • 1Artificial Intelligence and Drug Discovery (AIDD), Core Laboratory for District of Columbia Center of AIDS Research (DC CFAR), Washington, D.C. 20052, United States.

ACS Omega
|December 22, 2025
PubMed

Insights

Polyethylene glycol (PEG) conjugation alters the structure of pertuzumab, a HER2-targeted antibody, impacting its effectiveness. Larger PEG sizes cause significant structural changes, potentially reducing antibody binding and effector function for breast cancer treatment.

Area of Science:

  • Biochemistry
  • Structural Biology
  • Computational Biology

Background:

  • HER2 overexpression drives aggressive breast cancer, necessitating treatments like trastuzumab and pertuzumab.
  • Current antibody therapies face limitations in pharmacokinetics and tumor penetration.
  • Polyethylene glycol (PEG) conjugation can improve drug half-life but may affect antibody function.

Purpose of the Study:

  • To computationally investigate the structural impact of PEGylation on the pertuzumab Fc domain.
  • To quantify how different PEG sizes affect antibody pharmacokinetics and effector functions.
  • To provide a molecular basis for designing improved PEGylated monoclonal antibodies.

Main Methods:

  • Utilized a multiscale computational framework including AlphaFold2 and RoseTTAFold2 for structural modeling.
  • Incorporated G0F-type glycans and performed site-specific PEGylation using UCSF ChimeraX.
  • Conducted all-atom molecular dynamics simulations in GROMACS for control and PEGylated variants (1, 2, and 4 kDa).
  • Analyzed structural changes using RMSD, RMSF, principal component analysis, and hydrogen bond analysis.

Main Results:

  • Increasing PEG size led to stepwise increases in RMSD and hinge region expansion.
  • PEGylation induced domain-specific mobility shifts, with larger PEG sizes causing CH2/CH3 destabilization.
  • Principal component analysis revealed altered domain dynamics in PEGylated forms, particularly with 4 kDa PEG.
  • Identified structural disruptions in interdomain hydrogen bonds, suggesting reduced Fc receptor engagement.

Conclusions:

  • PEGylation introduces size-dependent structural perturbations in the pertuzumab Fc domain.
  • These structural changes provide a molecular explanation for potentially diminished HER2 binding affinity.
  • Findings guide the rational design of PEGylated monoclonal antibodies with optimized pharmacokinetics and preserved effector functions.